Louisiana Urges Supreme Court to Block Nationwide Mailing of Abortion Pills
A high-stakes legal battle over access to medication abortion has reached the U.S. Supreme Court. Louisiana state attorneys are urging the justices to uphold a lower court ruling that would effectively ban the mailing of mifepristone, one of the most common drugs used for abortion in the United States, nationwide.
The dispute centers on whether federal regulations allowing the drug to be sent via mail undermine state-level abortion bans. With a temporary stay set to expire on Monday, May 11, the Supreme Court must decide if the drug remains widely available or if patients must return to obtaining the medication in person from a physician.
The Legal Conflict: 5th Circuit vs. FDA
The current crisis was triggered last week when the conservative 5th Circuit Court of Appeals in New Orleans ruled in favor of Louisiana. The court revived an older regulation requiring women to obtain mifepristone in person from a doctor, taking the unusual step of making the order effective immediately.
However, the immediate impact of that ruling was paused on Monday. Justice Samuel A. Alito Jr., who oversees the 5th Circuit, issued an administrative stay that keeps the case on hold through Monday, May 11. This pause gives the Supreme Court time to consider emergency appeals from two mifepristone manufacturers, who argue that the pills are safe and effective for ending early pregnancies.
Louisiana’s Argument: “Undermining” State Law
Louisiana Attorney General Liz Murrill has led the charge to block mail-order access, arguing that the federal government’s flexibility is a direct assault on state sovereignty. In a filing submitted Thursday, Murrill claimed the Biden administration intentionally designed its policies to undermine the Supreme Court’s 2022 Dobbs decision, which overturned Roe v. Wade.
Murrill asserted that the lack of an in-person dispensing requirement allows out-of-state prescribers to bypass Louisiana’s strict abortion prohibitions. According to the Attorney General, this loophole is “causing approximately 1,000 illegal abortions in Louisiana each month by mailing FDA-approved mifepristone into the state.”
The Role of the FDA and HHS
Mifepristone was approved by the Food and Drug Administration (FDA) in 2000. Over the last decade, the agency relaxed several restrictions to increase patient access, including the requirement for an in-person clinic visit.
The current legal challenge coincides with a renewed safety review. Health and Human Services Secretary Robert F. Kennedy Jr. Agreed to have the FDA review the drug’s safety record in response to anti-abortion advocates. However, the FDA reported last month that this review is “far from complete.”
Despite the ongoing review, Attorney General Murrill chose to bypass the administrative process in October, seeking a federal court ruling to stop the mailing of the pills immediately.
Precedent and Judicial Outlook
The Supreme Court’s eventual decision may be influenced by its own history with similar challenges. Two years ago, the justices dismissed a nearly identical challenge to mifepristone regulations in a 9-0 vote. Chief Justice John G. Roberts has previously indicated that the judiciary should generally defer to the expertise of federal agencies, like the FDA, when regulating pharmaceuticals.
The core questions the justices must now answer are whether Louisiana has the legal standing to sue over these federal regulations and whether the court has the authority to overrule the FDA’s established protocols.
Key Takeaways: The Mifepristone Legal Battle
- The Request: Louisiana wants the Supreme Court to uphold a 5th Circuit ruling blocking the nationwide mailing of mifepristone.
- The Deadline: A temporary stay by Justice Samuel Alito Jr. Expires on Monday, May 11.
- The Conflict: Louisiana claims mail-order pills facilitate roughly 1,000 illegal abortions per month in the state.
- The Defense: Drug manufacturers argue the medication is safe, effective, and should remain accessible.
- The Regulatory Status: The FDA is currently conducting a safety review requested by HHS Secretary Robert F. Kennedy Jr., though it is not yet complete.
As the Monday deadline approaches, the decision will have immediate implications for reproductive healthcare access across the country, determining whether the FDA’s modern distribution guidelines or Louisiana’s strict in-person requirements prevail.